Denali Therapeutics Inc. Common Stock (DNLI) is a publicly traded Healthcare sector company. As of July 10, 2026, DNLI trades at $27.15 with a market cap of $4.24B and a P/E ratio of -9.09. DNLI moved +1.93% today. Year to date, DNLI is +64.81%; over the trailing twelve months it is +81.40%. Its 52-week range spans $10.57 to $27.30. Analyst consensus is strong buy with an average price target of $34.33. Rallies surfaces DNLI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Denali to Showcase BBB Drug Delivery Platform and Phase 1b Dosing at AAIC: Denali CEO Ryan Watts will deliver the opening plenary at AAIC in London on July 12, 2026, highlighting advances in the TransportVehicle platform for biologic delivery across the blood-brain barrier. The platform underpins FDA-approved AVLAYAH and supports investigational candidates DNL628 (Phase 1b dosed) and DNL921 (CTA submitted).
| Metric | Value |
|---|---|
| Price | $27.15 |
| Market Cap | $4.24B |
| P/E Ratio | -9.09 |
| EPS | $-2.97 |
| Dividend Yield | 0.00% |
| 52-Week High | $27.30 |
| 52-Week Low | $10.57 |
| Volume | 1.31M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-512.54M |
| Gross Margin | 0.00% |
12 analysts cover DNLI: 0 strong buy, 12 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $34.33.